553 related articles for article (PubMed ID: 28000533)
1. Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors.
Jin C; Yu D; Essand M
Immunotherapy; 2016 Dec; 8(12):1355-1361. PubMed ID: 28000533
[TBL] [Abstract][Full Text] [Related]
2. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
3. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
4. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
5. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.
Beavis PA; Slaney CY; Kershaw MH; Gyorki D; Neeson PJ; Darcy PK
Semin Immunol; 2016 Feb; 28(1):64-72. PubMed ID: 26611350
[TBL] [Abstract][Full Text] [Related]
6. CAR T-cell therapy of solid tumors.
Yong CSM; Dardalhon V; Devaud C; Taylor N; Darcy PK; Kershaw MH
Immunol Cell Biol; 2017 Apr; 95(4):356-363. PubMed ID: 28003642
[TBL] [Abstract][Full Text] [Related]
7. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
8. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
10. Engineering CAR-T Cells for Improved Function Against Solid Tumors.
Morgan MA; Schambach A
Front Immunol; 2018; 9():2493. PubMed ID: 30420856
[TBL] [Abstract][Full Text] [Related]
11. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
13. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials.
Arabi F; Torabi-Rahvar M; Shariati A; Ahmadbeigi N; Naderi M
Exp Cell Res; 2018 Aug; 369(1):1-10. PubMed ID: 29758187
[TBL] [Abstract][Full Text] [Related]
14. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
Ramachandran M; Dimberg A; Essand M
Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
[TBL] [Abstract][Full Text] [Related]
15. Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?
Hombach AA; Abken H
Expert Rev Clin Immunol; 2017 Feb; 13(2):151-155. PubMed ID: 27546707
[TBL] [Abstract][Full Text] [Related]
16. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor-redirected T cells return to the bench.
Geldres C; Savoldo B; Dotti G
Semin Immunol; 2016 Feb; 28(1):3-9. PubMed ID: 26797495
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
19. [Mechanisms of resistance and escape to CAR-T cells].
Grinda T; Brouard J; Tran D; Rubio MT
Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
